WallStSmart

BP PLC ADR (BP)vsBoston Scientific Corp (BSX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BP PLC ADR generates 835% more annual revenue ($187.64B vs $20.07B). BSX leads profitability with a 14.4% profit margin vs 0.0%. BP appears more attractively valued with a PEG of 0.18. BSX earns a higher WallStSmart Score of 63/100 (C+).

BP

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 4.5Value: 4.7Quality: 5.0

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BPSignificantly Overvalued (-4001.1%)

Margin of Safety

-4001.1%

Fair Value

$0.94

Current Price

$44.79

$43.85 premium

UndervaluedFair: $0.94Overvalued
BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BP3 strengths · Avg: 9.0/10
PEG RatioValuation
0.1810/10

Growing faster than its price suggests

Market CapQuality
$114.71B9/10

Large-cap with strong market position

Free Cash FlowQuality
$4.14B8/10

Generating 4.1B in free cash flow

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

Areas to Watch

BP4 concerns · Avg: 3.5/10
Price/BookValuation
13.0x4/10

Trading at 13.0x book value

Revenue GrowthGrowth
3.6%4/10

3.6% revenue growth

Return on EquityProfitability
1.7%3/10

ROE of 1.7% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : BP

The strongest argument for BP centers on PEG Ratio, Market Cap, Free Cash Flow. PEG of 0.18 suggests the stock is reasonably priced for its growth.

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bear Case : BP

The primary concerns for BP are Price/Book, Revenue Growth, Return on Equity. A P/E of 2239.0x leaves little room for execution misses. Thin 0.0% margins leave little buffer for downturns.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Key Dynamics to Monitor

BP profiles as a value stock while BSX is a growth play — different risk/reward profiles.

BSX carries more volatility with a beta of 0.70 — expect wider price swings.

BSX is growing revenue faster at 15.9% — sustainability is the question.

BP generates stronger free cash flow (4.1B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 54/100) and 15.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

BP PLC ADR

ENERGY · OIL & GAS INTEGRATED · USA

BP plc participates in the energy business globally. The company is headquartered in London, the United Kingdom.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Want to dig deeper into these stocks?